Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Core Insights - Nektar Therapeutics reported a quarterly loss of $1.78 per share, which was better than the Zacks Consensus Estimate of a loss of $2.76, representing an earnings surprise of +35.47% [1] - The company generated revenues of $21.81 million for the quarter, exceeding the Zacks Consensus Estimate by 128.59%, although this is a decline from $29.17 million in the same quarter last year [2] Financial Performance - Over the last four quarters, Nektar has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$2.14 on revenues of $9.62 million, and for the current fiscal year, it is -$10.65 on revenues of $40.23 million [7] Stock Performance - Nektar shares have increased by approximately 73.4% since the beginning of the year, contrasting with a 1% decline in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Nektar belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Plus Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.03 per share, reflecting a year-over-year change of +95.5% [9]